Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.59 |
| ▸ | BRAF | P15056 | 3/20 | 0.59 |
| ▸ | KCNJ6 | P48051 | 9/20 | 0.54 |
| ▸ | KCNJ3 | P48549 | 9/20 | 0.54 |
| ▸ | KCNJ5 | P48544 | 7/20 | 0.54 |
| ▸ | RAF1 | P04049 | 5/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | PLK4 | O00444 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243108 | 0.98 | MAPK14 (0.59) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2241234 | 0.91 | MAPK14 (0.58) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2240958 | 0.91 | KCNJ6 (0.56) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2242892 | 0.91 | MAPK14 (0.48) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2240648 | 0.90 | MAPK14 (0.58) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2240373 | 0.90 | KCNJ6 (0.54) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2240721 | 0.90 | KCNJ6 (0.58) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2240618 | 0.89 | ABL1 (0.58) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2241236 | 0.89 | MAPK14 (0.48) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2243426 | 0.89 | MAPK14 (0.62) | MAPK14BRAFKCNJ6KCNJ3KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | claimed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | MAPK14 3645/4885BRAF 338/4885KCNJ6 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.